HTFL HEARTFLOW INC

Heartflow to Participate in the Morgan Stanley Technology, Media & Telecom Conference

Heartflow to Participate in the Morgan Stanley Technology, Media & Telecom Conference

MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley Technology, Media & Telecom Conference. The presentation will take place in San Francisco, CA, on Tuesday, March 3, 2026, at 10:45 a.m. PT / 1:45 p.m. ET.

A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at .

About Heartflow’s Technology and Research

Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by ACC/AHA guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 500,000 patients worldwide.1 Key benefits include:

  • Proprietary data pipeline: Built from more than 160 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.
  • Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.
  • Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
  • Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001.



About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The  platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at .

Investor Contact

Nick Laudico

Media Contact

Elliot Levy

____________________

1Gulati, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. J Am Coll Cardiol.



EN
18/02/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HEARTFLOW INC

 PRESS RELEASE

Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results

Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Highlights Total revenue of $49.1 million, a 40% increase year-over-yearGross margin of 79.5%, non-GAAP gross margin of 79.9%Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5 millionU.S. installed base of 1,465 accounts...

 PRESS RELEASE

Heartflow Builds Evidence Base Across the Heart Disease Care Continuum...

Heartflow Builds Evidence Base Across the Heart Disease Care Continuum, From Precision Risk Stratification to CT-Guided Intervention Planning Three presentations at ACC reinforce Heartflow’s AI-powered technology predicts MACE, drives superior lipid outcomes and results in cost-effective care First patient enrolled in pioneering NAVIGATE-PCI Registry assessing impact of Heartflow PCI Navigator on clinical strategy, efficiency and physician confidence across 5,000 patients  MOUNTAIN VIEW, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- (Heartflow) (Nasdaq: HTFL), the leader in AI technology f...

 PRESS RELEASE

Heartflow to Participate in the Morgan Stanley Technology, Media & Tel...

Heartflow to Participate in the Morgan Stanley Technology, Media & Telecom Conference MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley Technology, Media & Telecom Conference. The presentation will take place in San Francisco, CA, on Tuesday, March 3, 2026, at 10:45 a.m. PT / 1:45 p.m. ET. A live and archived version of the fireside chat will be available on the Inves...

 PRESS RELEASE

Heartflow to Report Fourth Quarter and Full Year 2025 Financial Result...

Heartflow to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the fourth quarter and full year of 2025 after market close on Wednesday, March 18, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on March 18, 2026. Those interested in listening to the conference call should . Once r...

 PRESS RELEASE

Heartflow Expands GAMEFILM Registry to NBA and NHL Alumni, Precisely M...

Heartflow Expands GAMEFILM Registry to NBA and NHL Alumni, Precisely Measuring Heart Disease Risk in Former Professional Athletes NBA legend Muggsy Bogues joins effort to detect and manage coronary artery disease in retired players using AI-powered Heartflow Analysis MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced a significant expansion of its groundbreaking . Building on a successful initial phase enrolling retired National Football League (NFL) athletes, the study will...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch